Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

Journal of Experimental Medicine

Volumn 201, Issue 10, 2005, Pages 1591-1602

  Ercolini, Anne M ^a,b   Ladle, Brian H ^a,b   Manning, Elizabeth A ^a,b   Pfannenstiel, Lukas W ^a,b   Armstrong, Todd D ^a,b   Machiels, Jean Pascal H ^a,b   Bieler, Joan G ^b   Emens, Leisha A ^a,b   Reilly, R Todd ^a,b   Jaffee, Elizabeth M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR ALPHA; TETRAMER; VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL POPULATION; GENE TARGETING; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY; TUMOR IMMUNOLOGY; TUMOR REJECTION; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GENES, ERBB-2; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-2; VACCINATION;

EID: 21144454780     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20042167     Document Type: Article

References (48)

1. Sprent, J., and H. Kishimoto. 2002. The thymus and negative selection. Immunol. Rev. 185:126-135.
2. Walker, L.S., and A.K. Abbas. 2002. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:11-19.
3. O'Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10:801-805.
4. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807-839.
5. Disis, M.L., and M.A. Cheever. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71: 343-371.
6. Novellino, L., C. Castelli, and G. Parmiani. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54:187-207.
7. Hernandez, J., A. Ko, and L.A. Sherman. 2001. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166:3908-3914.
8. Morgan, D.J., H.T. Kreuwel, S. Fleck, H.I. Levitsky, D.M. Pardoll, and L.A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643-651.
9. Liu, G.Y., P.J. Fairchild, R.M. Smith, J.R. Prowle, D. Kioussis, and D.C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3:407-415.
10. Sprent, J., and S.R. Webb. 1995. Intrathymic and extrathymic clonal deletion of T cells. Curr. Opin. Immunol. 7:196-205.
11. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2863-2870.
12. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187:1555-1564.
13. De Visser, K.E., T.A. Cordaro, H.W. Kessels, F.H. Tirion, T.N. Schumacher, and A.M. Kruisbeek, 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167:3818-3828.
14. Klausner, R.D. 1999. Studying cancer in the mouse. Oncogens. 20;18: 5249-5252.
15. Guy, C.T., M.A. Webster, M. Schaller, T.J. Parsons, R.D. Cardiff, and W.J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89:10578-10582.
16. Reilly, R.T., M.B. Gottlieb, A.M. Ercolini, J.P. Machiels, C.E. Kane, F.I. Okoye, W.J. Muller, K.H. Dixon, and E.M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569-3576.
17. Machiels, J.P., R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, D. Weintraub, F.I. Okoye, and E.M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3689-3697.
18. North, R.J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155:1063-1074.
19. Hoover, S.K., S.K. Barrett, T.M. Turk, T.C. Lee, and H.D. Bear. 1990. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother. 31:121-127.
20. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34:336-344.
21. Turk, M.J., J.A. Guevara-Patino, G.A. Rizzuto, M.E. Engelhorn, S. Sakaguchi, and A.N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 20:200:771-782.
22. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-296.
23. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
24. Ercolini, A.M., J.P. Machiels, Y.C. Chen, J.E. Slansky, M. Giedlen, R.T. Reilly, and E.M. Jaffee. 2003. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 170:4273-4280.
25. d, and two genes reported to encode tumor-specific antigens. J. Exp. Med. 168:1719-1739.
26. Savage, P.A., J.J. Boniface, and M.M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 10:485-492.
27. Cawthon, A.G., H. Lu, and M. Alexander-Miller. 2001. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J. Immunol. 167:2577-2584.
28. + regulatory T cells in vivo. J. Exp. Med. 198:249-258.
29. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-3133.
30. + T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. J. Immunol. 164:191-200.
31. + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34:752-761.
32. Busch, D.H., and E.G.P. Am. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189:701-710.
33. Alexander-Miller, M.A., G.R. Leggatt, and J.A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA. 93: 4102-4107.
34. Dutoit, V., V. Rubio-Godoy, M.A. Doucey, P. Batard, D. Lienard, D. Rimoldi, D. Speiser, P. Guillaume, J.C. Cerottini, P. Romero, and D. Valmori. 2002. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168:1167-1171.
35. Dutoit, V., V. Rubio-Godoy, P.Y. Dietrich, A.L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Lienard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61:5850-5856.
36. Yee, C., P.A. Savage, P.P. Lee, M.M. Davis, and P.D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234.
37. Yang, S., G.P. Linette, S. Longerich, and F.G. Haluska. 2002. Anti-melanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. 169:531-539.
38. Zeh, H.J., III, D. Perry-Lalley, M.E. Dudley, S.A. Rosenberg, and J.C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994.
39. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601.
40. Yang, Y., C.T. Huang, X. Huang, and D.M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5:508-515.
41. Nigam, A., R.F. Yacavone, M.L. Zahurak, C.M. Johns, D.M. Pardoll, S. Piantadosi, H.I. Levitsky, and W.G. Nelson. 1998. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int. J. Oncol. 12:161-170.
42. Hernandez, J., P.P. Lee, M.M. Davis, and L.A. Sherman. 2000. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol. 164:596-602.
43. Derby, M.A., J. Wang, D.H. Margulies, and J.A. Berzofsky. 2001. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13:817-824.
44. Rubio-Godoy, V., V. Dutoit, D. Rimoldi, D. Lienard, F. Lejeune, D. Speiser, P. Guillaume, J.C. Cerottini, P. Romero, and D. Valmori. 2001. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc. Natl. Acad. Sci. USA. 98:10302-10307.
45. + T cell peripheral tolerance in non-obese diabetic mice. J. Immunol. 167:1112-1117.
46. Heath, W.R., C. Kurts, J.F. Miller, and F.R. Carbone. 1998. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187:1549-1553.
47. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32.
48. Altman, J.D., P.A. Moss, P.J. Goulder, D.H. Barouch, M.G. Heyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.